CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
Dronabinol +1 moredrug
Likely dose
Dronabinol 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00946348
NCT00946348Phase 1Completed
CompareCT.gov

Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

Dartmouth-Hitchcock Medical Center·interventional·Posted Jul 27, 2009·Updated Jul 12, 2021

In Brief

A Phase 1 clinical trial evaluating Dronabinol and Cannabis for Schizophrenia and 4 related conditions. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol. The second aim will serve to further assess the effects of dronabinol on symptoms and medication side effects in this population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Indiana University, Columbia University, University of Vermont, University of Massachusetts, Worcester

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 27, 2009
Enrollment StartDec 1, 2009
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.9 years ago

Interventions

Dronabinoldrug

Dronabinol 10 mg or 15 mg

Cannabisdrug

Cannabis cigarette